Improvement of Skeletal and Muscle Health in Patients With Sarcopenia by Protein Powder With Resistance Exercise
NCT ID: NCT07049731
Last Updated: 2025-07-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
224 participants
INTERVENTIONAL
2025-08-31
2027-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Intervention Assessing the Role of Exercise Program and Nutrition Supplement for Sarcopenia
NCT02374268
The Effect of a Multi-intervention Program and Protein Food Sources on Preventing and Mitigating Sarcopenia
NCT06173271
Protein Supplementation Intervention for Improving Muscle Mass and Physical Performance in Older People With Sarcopenia
NCT04516421
Prevalence and Effect of Lifestyle Modification on Clinical Outcomes and Cost-effectiveness Ratio for Sarcopenia
NCT02873676
Effect of Low Intensity Exercise and Protein Intake on Skeletal Muscle Protein Synthesis in Elderly
NCT01640145
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo control group
Placebo control
placebo was given and an individualized balanced dietary plan based on the Dietary Guidelines for Chinese Residents was provided.
Protein powder intervention group
Protein powder intervention
On the basis of a balanced diet, 2 sachets of Aiben Leap Protein Nutritional Powder (each sachet containing 6g of milk protein) were supplemented daily.
Resistance exercise+placebo control group
Resistance exercise intervention
Low-intensity resistance training was conducted 3 times a week.
Placebo control
placebo was given and an individualized balanced dietary plan based on the Dietary Guidelines for Chinese Residents was provided.
Resistance exercise + protein powder intervention group
Protein powder intervention
On the basis of a balanced diet, 2 sachets of Aiben Leap Protein Nutritional Powder (each sachet containing 6g of milk protein) were supplemented daily.
Resistance exercise intervention
Low-intensity resistance training was conducted 3 times a week.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Protein powder intervention
On the basis of a balanced diet, 2 sachets of Aiben Leap Protein Nutritional Powder (each sachet containing 6g of milk protein) were supplemented daily.
Resistance exercise intervention
Low-intensity resistance training was conducted 3 times a week.
Placebo control
placebo was given and an individualized balanced dietary plan based on the Dietary Guidelines for Chinese Residents was provided.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Grip strength less than 28.0 kg for males and less than 18.0 kg for females
2. 6-meter stride speed less than 1.0 m/s or 5-repetition sit-up test time ≥ 12 seconds or SPPB ≤ 9 points.
3. Bioelectrical Impedance Analysis (BIA) less than 7.0 kg/m² for males and 5.7 kg/m² for females or Dual-energy X-ray absorptiometry (DXA) less than 7.0 kg/m² for males and 5.4 kg/m² for females;
* Age between 35-75 years old with high compliance;
* Complete clinical data;
* Voluntary participation in the program with informed consent and signing of the informed consent form.
Exclusion Criteria
* Major physical diseases (diabetes with serious complications, malignant tumors, serious cardiovascular disease, neurological diseases or other diseases that may affect the effectiveness of exercise and nutritional interventions, etc.);
* The past three months, new fractures and recently underwent joint replacement surgery patients;
* Suffering from congenital bone or muscle diseases;
* The simultaneous existence of other comorbidities affecting muscle metabolism, such as malignant tumors, liver disease, severe organ insufficiency such as nephrotic syndrome, renal failure and other diseases that may affect protein metabolism;
* Participating in other clinical trials patients;
* With sensory disabilities or other reasons significantly affecting the collection of data, such as severe deafness, blindness, mental disorders, etc.;
* The researchers The researchers believe that other reasons are not suitable for clinical trials.
35 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beijing Jishuitan Hospital, Capital Medical University
UNKNOWN
Capital Medical University
OTHER
Beijing Friendship Hospital
OTHER
Weiwei Ma
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Weiwei Ma
professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Capital Medical University
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Z2025SY021
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.